<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162381</url>
  </required_header>
  <id_info>
    <org_study_id>0105-14-RMC</org_study_id>
    <nct_id>NCT02162381</nct_id>
  </id_info>
  <brief_title>Methylphenidate Effect on Humphrey Visual Fields</brief_title>
  <official_title>Methylphenidate Effect on Performing Humphrey Visual Fields</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study will include adults with abnormal visual fields. Half of them will be given either
      methylphenidate 10mg 2 hours before repeating the visual field test. the rest will serve as
      controls. All Subjects will also have a complete eye examination, a short questionnaire and a
      questionnaire to screen for attention deficit disorder. The investigators will compare the
      visual field results between the 2 tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy adults with abnormal visual fields will be offered to participate Subjects will have
      a complete ophthalmic examination including dilated fundus examination.

      Subjects with clear explanation for a visual field defect (e.g. optic neuropathy or retinal
      disorder) will be excluded from the study the subjects will be randomly assigned to the study
      group and control group using a 1:1 allocation.

      Subjects in the study group will be provided with a single tablet of methylphenidate 10 mg to
      be taken orally 2 hours before repeating their visual field test.

      The control group will not receive any placebo Both groups will repeat their visual fields.
      Both groups will fill out a short questionnaire to evaluate their experience in the second
      visual field test.

      The study group will also fill out a screening questionnaire to rule out previously
      undiagnosed attention deficit disorder.

      Two experienced ophthalmologists will separately interpret the visual fields results and
      compare the first and second visual fields of each subject, while being blinded to which
      group he was in.

      Subjects will be provided with their test results and the ophthalmologist interpretation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement rate of a repeat visual field result</measure>
    <time_frame>immediate</time_frame>
    <description>the percentage of subjects whose second (repeat) visual field has improved compared to the first visual field - as interpreted by independent blinded ophthalmologists</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humphrey visual field Mean Deviation (MD)</measure>
    <time_frame>immediate</time_frame>
    <description>the MD of the Humphrey visual field in the study and control groups will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humphrey visual field severity score</measure>
    <time_frame>immediate</time_frame>
    <description>based on the Humphrey visual field gray scale each visual field will be given a score between 1 and 4. 1 = normal 2=enlargement of the blind spot 3=either a nasal or temporal visual field 4= diffuse visual field loss</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Visual Field Tests</condition>
  <arm_group>
    <arm_group_label>methylphenidate provided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate</intervention_name>
    <description>a single dose of methylphenidate 10 mg to be taken orally in the morning</description>
    <arm_group_label>methylphenidate provided</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>guidance</intervention_name>
    <description>subjects will be given an explanation and advice about how to perform well in visual field testing</description>
    <arm_group_label>methylphenidate provided</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  abnormal visual fields

          -  must be able to swallow pills

        Exclusion Criteria:

          -  psychiatric disorder

          -  dementia

          -  ocular disorder which is known to cause abnormal visual fields

          -  prescription of psychoactive medications

          -  visual acuity lower than 20/100

          -  cardiac arrhythmia

          -  hypersensitivity to methylphenidate

          -  prescription of warfarin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Y Bialer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Martin L, Aring E, Landgren M, Hellström A, Andersson Grönlund M. Visual fields in children with attention-deficit / hyperactivity disorder before and after treatment with stimulants. Acta Ophthalmol. 2008 May;86(3):259-64. doi: 10.1111/j.1755-3768.2008.01189.x.</citation>
    <PMID>18494726</PMID>
  </reference>
  <reference>
    <citation>Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000 Jul;75(7):711-21. Review.</citation>
    <PMID>10907387</PMID>
  </reference>
  <reference>
    <citation>Dodson WW. Pharmacotherapy of adult ADHD. J Clin Psychol. 2005 May;61(5):589-606. Review.</citation>
    <PMID>15723384</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Bialer</investigator_full_name>
    <investigator_title>Dr. Omer Y. Bialer</investigator_title>
  </responsible_party>
  <keyword>Humphrey visual fields</keyword>
  <keyword>methylphenidate</keyword>
  <keyword>attention deficit disorder</keyword>
  <keyword>MoCa questionnaire</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

